Novo Holding
3
126M
2
0.14
0.33
2
- Areas of investment
Summary
Novo Holding appeared to be the Corporate Investor, which was created in 1999. The venture was found in Europe in Sweden. The main office of represented Corporate Investor is situated in the Lund.
Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. Among the most successful fund investment fields, there are Biopharma, Pharmaceutical. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has exact preference in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Harmony Biosciences, Spruce Biosciences.
The standard case for the fund is to invest in rounds with 4-5 partakers. The meaningful sponsors for the fund in investment in the same round are venBio Partners, Vivo Capital, Valor Equity Partners. In the next rounds fund is usually obtained by CRG L.P..
The fund is constantly included in less than 2 investment rounds annually. The high activity for fund was in 2017. Deals in the range of more than 100 millions dollars are the general things for fund.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 0
- Exits
- 2
- Rounds per year
- 0.14
- Follow on index
- 0.33
- Investments by industry
- Biopharma (3)
- Biotechnology (3)
- Health Care (3)
- Pharmaceutical (2)
- Investments by region
-
- United States (3)
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Group Appearance index
- 1.00
- Strategy success index
- 0.75
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Spruce Biosciences | 02 Jan 2016 | Biotechnology, Health Care, Pharmaceutical, Biopharma | Early Stage Venture | 20M | United States, California, San Francisco |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.